Oppenheimer Upgrades Genoptix (GXDX) to Outperform
More News related to GXDX
- Genoptix Announces Participation at Lazard Capital Management 6th Annual Healthcare Conference
- Auriga Reiterates a 'Buy' on Genoptix (GXDX); Unique Growth Story
- Genoptix (GXDX) Rops Q3 EPS by 21c; Guides Higher for FY09; 2010 Revs In-line
- Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to Upgrades
- Regency Energy (RGNC) Announces 10M Unit Public Offering
- SWS Group (SWS) Commences 4.1M Share Equity Offering
- GeoResources (GEOI) Closes 3.45M Share Offering for Proceeds of $33M
- U.S. Energy (USEG) to Offer 5M Shares of Common Stock
- Acuity Brands (AYI) Announces $400M Senior Unsecured Note Private Offering
Oppenheimer upgrades Genoptix (Nasdaq: GXDX) from Perform to Outperform. Price target increased from $33 to $44.
To see more analyst ratings on GXDX Click Here.
Genoptix, Inc. (Genoptix) is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists (hema/oncs).
Related Categories
UpgradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
